Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 8/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.56 |
| ▸ | ESR1 | P03372 | 1/20 | 0.55 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.55 |
| ▸ | PRF1 | P14222 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | HSD17B1 | P14061 | 4/20 | 0.44 |
| ▸ | HSD17B2 | P37059 | 4/20 | 0.44 |
| ▸ | NQO2 | P16083 | 1/20 | 0.43 |
| ▸ | SNCA | P37840 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12372828 | 0.90 | APP (0.81) | APPCYP3A4TDP1ALDH1A1TP53 | |
| SCHEMBL12973258 | 0.88 | APP (1.00) | APPCYP3A4ALDH1A1ESR1ESR2 | |
| SCHEMBL12973225 | 0.88 | APP (0.77) | APPCYP3A4TDP1ALDH1A1TP53 | |
| SCHEMBL9912044 | 0.87 | APP (0.76) | APPCYP3A4TDP1ALDH1A1TP53 | |
| SCHEMBL21427066 | 0.86 | APP (0.74) | APPCYP3A4TDP1ALDH1A1ESR1 | |
| SCHEMBL21427063 | 0.86 | APP (0.74) | APPCYP3A4TDP1ALDH1A1ESR1 | |
| SCHEMBL11896154 | 0.83 | APP (0.70) | APPCYP3A4TDP1ALDH1A1TP53 | |
| SCHEMBL12973259 | 0.82 | APP (1.00) | APPCYP3A4TDP1ALDH1A1TP53 | |
| SCHEMBL11113150 | 0.78 | APP (0.61) | APPALDH1A1ESR1ESR2MEN1 | |
| SCHEMBL12491723 | 0.74 | APP (0.58) | APPCYP3A4ALDH1A1TP53ESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2019189416-A1 | LIQUID CRYSTAL ALIGNMENT AGENT, LIQUID CRYSTAL ALIGNMENT FILM, AND LIQUID CRYSTAL DISPLAY ELEMENT | 日産化学株式会社 | 2019-10-03 | — | — | WO | disclosed |
| WO-2019182072-A1 | POLYUREA COPOLYMER, LIQUID CRYSTAL ALIGNMENT AGENT, LIQUID CRYSTAL ALIGNMENT FILM, AND LIQUID CRYSTAL DISPLAY ELEMENT USING SAME | 日産化学株式会社 | 2019-09-26 | — | — | WO | disclosed |
| US-8735398-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-05-27 | — | — | US | disclosed |
| US-8735398-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-05-27 | — | — | US | disclosed |
| US-20130085147-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-04-04 | — | — | US | disclosed |
| US-20130085147-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-04-04 | — | — | US | disclosed |
| US-8362020-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-01-29 | — | — | US | disclosed |
| US-8362020-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-01-29 | — | — | US | disclosed |
| US-20110294819-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2011-12-01 | — | — | US | disclosed |
| US-20110294819-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2011-12-01 | — | — | US | disclosed |
| WO-2011082077-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-07-07 | — | — | WO | disclosed |
| US-7858072-B2 | Stilbene derivatives and their use for binding and imaging amyloid plaques | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2010-12-28 | — | — | US | disclosed |
| US-7858072-B2 | Stilbene derivatives and their use for binding and imaging amyloid plaques | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2010-12-28 | — | — | US | disclosed |
| US-20080167429-A1 | Nanoimprinting composition | CHISSO CORPORATION | 2008-07-10 | — | — | US | disclosed |
| US-20080167429-A1 | Nanoimprinting composition | CHISSO CORPORATION | 2008-07-10 | — | — | US | disclosed |
| US-20080003381-A1 | Overcoat film composition, color filter substrate, and liquid crystal display element | CHISSO CORPORATION | 2008-01-03 | — | — | US | disclosed |
| US-20080003381-A1 | Overcoat film composition, color filter substrate, and liquid crystal display element | CHISSO CORPORATION | 2008-01-03 | — | — | US | disclosed |
| US-6706754-B2 | ANTIPROTOZOA AGENTS, PARASITICIDES | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE ARMY | 2004-03-16 | — | — | US | disclosed |
| US-20020156098-A1 | Reversed amidines and methods of using for treating, preventing, or inhibiting leishmaniasis | ARMY, UNITED STATES | 2002-10-24 | — | — | US | disclosed |
| WO-2002036588-A2 | REVERSED AMIDINES AND METHODS OF USING FOR TREATING, PREVENTING, OR INHIBITING LEISHMANIASIS | U.S. ARMY MEDICAL RESEARCH AND MATERIEL COMMAND (US) | 2002-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110294819-A1 | Hepatitis C Virus Inhibitors | HAVCR2, MAVS, GTF3C1 | APP 4533/4885CYP3A4 2270/4885TDP1 3336/4885 |
| US-20130085147-A1 | Hepatitis C Virus Inhibitors | HAVCR2, MAVS, GTF3C1 | APP 4533/4885CYP3A4 2270/4885TDP1 3336/4885 |
| US-20020156098-A1 | Reversed amidines and methods of using for treating, preventing, or inhibiting leishmaniasis | ARG1, NAT1, CTSA | APP 4689/4885CYP3A4 3622/4885TDP1 1890/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.